

Sci Transl Med 10 October 2012:
Vol. 4, Issue 155, p. 155ra138
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3004414

Supplementary Materials for:

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow, Xuefei Shen, R. Lamar Parker, Jessica C. Lee, Mary Giffear, Panyupa Pankhong, Amir S. Khan, Kate E. Broderick, Christine Knott, Feng Lin, Jean D. Boyer, Ruxandra Draghia-Akli, C. Jo White, J. Joseph Kim, David B. Weiner, Niranjana Y. Sardesai*

*To whom correspondence should be addressed. E-mail: nsardesai@inovio.com

Published 10 October 2012, *Sci. Transl. Med.* **4**, 155ra138 (2012)
DOI: 10.1126/scitranslmed.3004414

This PDF file includes:

- Methods
- Fig. S1. HPV16 and HPV18 E7. specific seroconversion measured by Western blot at D1, D3+4, and D3+24 in the 0.3, 1.0, and 3.0 mg groups.
- Fig. S2. CD45RO and CD27 phenotyping of HPV-specific T cells after immunization.
- Fig. S3. Regression analysis of responses generated in cellular immune assays.
- Fig. S4. Regression analysis of frequency of preimmunization peripheral T_{regs} compared to postimmunization responses from cellular immune assays.
- Table S1. Severity of injection site reactions by cohort.
- Table S2. Severity of AEs by system organ class and preferred term.
- Table S3. Association between MHC class I HLA-A, HLA-B, and HLA-C types and vaccine-induced antigen-specific T cell responses.
- Table S4. Association between MHC class II HLA-DRB and HLA-DQB types and vaccine-induced antigen-specific T cell responses.

[\[Download PDF\]](#)

[Return to article](#)